Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GSK plc (GSK) vs Abrdn Physical Platinum Shares ETF (PPLT) Price & Performance

Abrdn Physical Platinum Shares ETFTrade

Price performance (Past 24H)

Key statistics

GSK plc vs Abrdn Physical Platinum Shares ETF — how do they compare? GSK plc trades at $50.45 (market cap $102.60B), while Abrdn Physical Platinum Shares ETF trades at $15.96. The key difference: GSK plc pays a 3.57% dividend while Abrdn Physical Platinum Shares ETF pays none, and GSK plc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.

GSKPPLT
Market Cap
$102.60B
Sector
HealthCommodities - Metals/Agriculture
52-Week High
$61.18$25.23
52-Week Low
$38.22$11.95
Enterprise Value
$123.04B
Dividend Yield
3.57%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GSK plc

GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.

GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.

Abrdn Physical Platinum Shares ETF

PPLT, the abrdn Physical Platinum Shares ETF, trades at $15.955, up 0.28% with a bullish technical signal from moving averages, though RSI levels above 74 suggest overbought conditions. The ETF holds physical platinum, benefiting from recent precious metals momentum, but key financial ratios like P/E and P/S are unavailable for this commodity trust. A 1:10 stock split is scheduled for May 26, 2026, which may affect liquidity.

The outlook hinges on platinum catching up to gold and silver rallies, as noted by financial media, but risks include commodity price volatility and zero dividends. Investment appeal lies in potential mean reversion in precious metals ratios, yet investors face exposure to industrial demand fluctuations and macroeconomic factors influencing platinum prices.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About GSK plc

In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.

Read more on GSK

About Abrdn Physical Platinum Shares ETF

PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.

Read more on PPLT